Published in Vestn Oftalmol on June 12, 2009
Endoplasmic reticulum stress-related factors protect against diabetic retinopathy. Exp Diabetes Res (2011) 0.87
[Molecular mechanisms of retinal ischemia]. Vestn Oftalmol (2010) 0.79
[Use of perindopril in the treatment of patients with diabetic retinopathy]. Vestn Oftalmol (2006) 0.79
[Oxidative stress in uveitis and its correction with superoxide dismutase antioxidative enzyme (experimental study)]. Vestn Oftalmol (2015) 0.76
[Functional diagnostics of retinal ischemia: Muller cells and neovascularization of the retina in diabetic retinopathy]. Vestn Oftalmol (2005) 0.76
[Regularities of morphological and functional changes in the retina in its detachment and after surgical treatment. Communication 1. Deconstruction and restoration of photoreceptors]. Vestn Oftalmol (2008) 0.75
[Reflex therapy, massage, and manual therapy in the treatment of progressive myopia in children and adolescents]. Vestn Oftalmol (2006) 0.75
[Regularities of morphological and functional changes in the retina in its detachment and after surgical treatment. Communication 2. Remodeling of the internal retina]. Vestn Oftalmol (2008) 0.75
[First experience of intrastromal ring segments insertion for correction of posttraumatic cicatricial corneal astigmatism]. Vestn Oftalmol (2014) 0.75
[Effects of dexamethasone and superoxide dismutase instillations on clinical course of uveitis and local biochemical processes (experimental study)]. Vestn Oftalmol (2015) 0.75
[Modern aspects of diabetic retinopathy and diabetic macular oedema treatment]. Vestn Ross Akad Med Nauk (2012) 0.75
[New aspects in the problem of retinal and optic nerve diseases]. Vestn Oftalmol (2001) 0.75
[Electroretinography in the evaluation of vitreoretinal proliferative changes due to penetrating shell injury to the eye]. Vestn Oftalmol (2007) 0.75
[Investigation of scleral fibronectin in primary open-angle glaucoma: immunohistochemical study]. Vestn Oftalmol (2009) 0.75
[Experience of garasone use in surgical practice]. Vestn Oftalmol (2001) 0.75
[ELISA-based determination of natural antibodies to endothelial NO-synthase in human blood and tear]. Klin Lab Diagn (2004) 0.75
[Complex ultrasound examination children with persisting hyperplastic primary vitreous]. Vestn Oftalmol (2011) 0.75
[Role of ultrasonic B-scanning in differential diagnosis and prognosis of the course of optic neuritis]. Vestn Oftalmol (2002) 0.75
[Eye care management in Russian Federation]. Vestn Oftalmol (2015) 0.75
[Prevention of spontaneous scleral perforation during repeated surgery for regmatogenic retinal detachment]. Vestn Oftalmol (2005) 0.75
[Impact of ozone therapy on the electrophysiological parameters of the retina in patients operated on for its rhegmatogenous detachment]. Vestn Oftalmol (2007) 0.75
[L-arginine in the lacrimal fluid of patients with diabetic retinopathy and the possible role of nitric oxide in the pathogenesis of retinal ischemia]. Vestn Oftalmol (2000) 0.75
[Topography and functional changes of the rabbit retina with a single injection of triamcinolone]. Vestn Oftalmol (2006) 0.75
[Angiographic research on the sequelae of fragmentation injuries of the eye]. Vestn Oftalmol (1986) 0.75
[Electroretinography in regmatogenic retinal detachment in the myopic eye]. Vestn Oftalmol (2009) 0.75
[Retinal ischemia and nitric oxide]. Vestn Ross Akad Med Nauk (2003) 0.75
[Risk factors of extraocular spread after local treatment of uveal melanoma]. Vestn Oftalmol (2011) 0.75
[Contemporary achievments in ophthalmotraumatology]. Vestn Ross Akad Med Nauk (2007) 0.75
[Intraocular correction of the aphakia in fragmentation wounds of the eye]. Vestn Oftalmol (1990) 0.75
[Ocular and orbital blood flow in patients with proliferative vitreoretinopathy associated with rhegmatogenous retinal detachment]. Vestn Oftalmol (2012) 0.75
[Methods of comprehensive multifunctional examination of patients with penetrating fragmentation injuries of eye]. Vestn Oftalmol (1998) 0.75
[Combined ultrasound study in the prediction of the results of surgical treatment for persistent hyperplastic primary vitreous body in children]. Vestn Oftalmol (2009) 0.75
[Indications for different methods of treatment for chemically active foreign bodies in the area of the posterior portion of the eye]. Oftalmol Zh (1983) 0.75
[Differential diagnosis of early central choroidal melanoma and late stage age-related macula degeneration]. Vestn Oftalmol (2013) 0.75
[Effects of ozone therapy on the functional activity of the retina in patients with involutional central chorioretinal dystrophy]. Vestn Oftalmol (2004) 0.75
[Surgical tactics in cases of metallic foreign bodies in the posterior segments of the eye]. Vestn Oftalmol (1986) 0.75
[Pulse therapy in the treatment of optic neuritis in multiple sclerosis]. Vestn Oftalmol (2003) 0.75
[Activity of angiotensin-converting enzyme in the blood and tear of patients with diabetic retinopathy]. Vestn Oftalmol (2006) 0.75
[Bases for resuscitation of the eye in its severe injury at the present stage]. Vestn Oftalmol (2010) 0.75
[Analysis of the clinical effectiveness of vitrum vision in the tired eye syndrome and senile macular degeneration]. Vestn Oftalmol (2005) 0.75
[Possibilities for prevention and treatment of blindness and impaired vision in children caused by congenital eye diseases]. Vestn Ross Akad Med Nauk (2007) 0.75
[The first experience of using OCT in diagnosis of primary and residual retinoblastoma]. Vestn Oftalmol (2012) 0.75
[Assessment of the clinical and functional results of laser coagulation of retinal drusen in the central zone of the eye grounds]. Vestn Oftalmol (2007) 0.75
[Clinical course and results of treatment of zone I retinopathy of prematurity]. Vestn Oftalmol (2013) 0.75
[Effect of the nitric oxide donors Na nitroprusside and L-arginine on the course of uveitis, the antioxidative and antiproteolytic potential of tear and blood in the experiment]. Vestn Oftalmol (2007) 0.75
[Factors influencing ocular angiogenesis]. Vestn Oftalmol (2009) 0.75
[Ocular blood flow assessment in normal subjects and in patients with hyperglycemia based on the results of ultrasonic examination in experiment]. Vestn Oftalmol (2013) 0.75
[Photodynamic therapy with visudine in combination with intravitreal kenalog in the treatment of choroidal neovascularization]. Vestn Oftalmol (2009) 0.75
[Role of rheoophthalmography in the evaluation of ocular hemodynamics in pregnant women with myopia]. Vestn Oftalmol (2008) 0.75